Oesophageal Cancer Trial, Recruiting NCT05327517 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT05327517
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of esophageal cancer (squamous cell carcinoma) in the neck area that can be removed with surgery, at certain stages of the disease
  • Your cancer may have spread upward toward the throat or downward toward the chest area
  • You are between 18 and 75 years old
  • You are considered well enough to safely have surgery (no medical reasons preventing it)
  • Your blood test results meet certain minimum levels for red blood cells, white blood cells, platelets, and how well your liver and kidneys are working (confirm specific values with trial site)
  • You do not have any other types of cancer
  • Your surgeon expects to be able to remove all of the cancer completely during the operation
  • You are generally active and able to carry out daily activities with little or no restriction (confirm with trial site)
  • You are willing to take part and have signed a consent form

Who may not be able to join:

  • You have another type of cancer in addition to this diagnosis
  • You have a mental health condition
  • You have a bleeding or blood clotting disorder
  • You are not considered a suitable candidate for surgery
  • You are pregnant or currently breastfeeding
  • You have had an allergic reaction in the past to the chemotherapy drugs paclitaxel or cisplatin

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jie He, MD, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Phone: +8613600892432

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
10 April 2022
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov